* If you want to update the article please login/register
Patients in the control group will receive standard therapy for 12 weeks, and patients in the intervention group will be given their standard therapy plus one sachet daily of lacteol forte sachets for 12 weeks. Both baseline and at the end of the study will be conducted at baseline and in the evaluation of disease activity using the validated Arabic LupusPROv1. 8 questionnaire, and Pain assessment using the validated Arabic version of the Short-Form McGill Pain Questionnaire. Laboratory samples for laboratory tests will be withheld at baseline and end of the investigation.
Source link: https://clinicaltrials.gov/ct2/show/NCT05433857
This research protocol will investigate subjects with systemic lupus erythematosus and their families to determine the disease's pathogenesis and natural history of the disease as well as the causes that cause increased organ damage. Any medical services provided to the patient or provided in collaboration with the patient's referring physician will be consistent with current guidelines of practice and provided in consultation with the patient's referring physician. Healthy volunteers for research purposes and to promote the identification and validation of new biomarker candidates will also be collected or applied to from healthy volunteers for research purposes.
Source link: https://clinicaltrials.gov/ct2/show/NCT00001372
This is a double blind placebo-controlled trial to determine whether blocking type I IFN receptor signaling with anifrolumab will result in improved cardiovascular function, decreases in vascular inflammation, and modulation of biomarkers of cardiovascular risk in patients with systemic lupus erythematosus. Objectives: Primary Objective: To determine the role of anifrolumab in modulating cardiovascular function and vascular inflammation in SLE patients with mild to moderate disease prevalence in Systemic Lupus Erythematosus Disease Activity Index 2K = 6. Secondary Objectives: According to SLEDAI 2K = 6, to determine how anifrolumab may be used in modulating biomarkers of cardiovascular risk in SLE patients with mild to moderate disease prevalence. Using Sphygmocor, you can go from baseline to Week 28 in pulse wave velocity. Using FDG PET CT scans, changes from baseline to Week 28 in vascular inflammation as measured by target to background ratio in several aortic territories and total aorta.
Source link: https://clinicaltrials.gov/ct2/show/NCT05440422
Younger female patients with SLE are more likely to experience myocardial infarction than matched healthy controls, and CVD is now one of the most common causes of death in lupus patients. Although traditional CV risk factors can't explain such increased CV morbidity associated with SLE, common disease causes identified among SLE, atherosclerosis, and treatment exposure may be of utmost importance in this process. Although traditional CV risk factors cannot explain such elevated CV risk factors, traditional CV risk factors cannot explain such heightened CV morbidity associated with SLE, common disease factors shared between SLE, atherosclerosis, and treatment exposure may be of utmost importance in this situation, 1/ the investigators found specific immunometabolites based on SLE patients' blood circulation, which are elevated in SLE patients's circulation. In SLE, the investigators discovered OX40L as an important costimulatory molecule involved in the initiation of follicular supporter T cell activation. SLE and atherosclerosis patients have been shown multiple pathways, which may lead to an elevated risk of CV-associated morbidity in SLE patients.
Source link: https://clinicaltrials.gov/ct2/show/NCT04276701
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions